查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1535584

重症监护诊断市场 - 按产品、测试类型、最终用途 - 全球预测

Critical Care Diagnostics Market - By Product, Test Type, End-use - Global Forecast
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在领先公司之间合作伙伴关係数量不断增加的推动下，2024 年至 2032 年间，全球重症监护诊断市场的复合年增长率将达到 5.5%。这些合作正在加强对重症监护环境至关重要的先进诊断技术的开发和推广。例如，2024 年 6 月，Radiometer 和 Etiometry 建立了新的商业合作伙伴关係，旨在改善医院环境中的临床决策和工作流程。根据此次合作，Etiometry 的平台将与 Radiometer 的急诊诊断解决方案集成，使重症监护临床医生能够在单一萤幕上获取血液气体结果、基本临床资料、其他生理参数和人工智慧驱动的患者风险分析。

这些工具对于准确、及时地诊断重症监护环境中的复杂状况至关重要。合作伙伴关係也有助于分担研发成本，提高效率并更快地将新产品推向市场。随着医疗保健提供者越来越需要精确可靠的诊断解决方案来管理重症患者，这些策略联盟对于满足此需求和推动市场成长至关重要。因此，重症监护诊断市场正在迅速扩大，反映出合作努力在推动医疗保健技术方面的重要性。

整个重症监护诊断行业根据产品、测试类型、最终用途和地区进行分类。

根据产品，心臟代谢诊断试剂盒领域的重症监护诊断市场收入将在2024 年至2032 年实现值得称讚的复合年增长率。重要，这些疾病在心臟病、糖尿病和代谢症候群等疾病中普遍存在。透过提供快速、准确的诊断讯息，心臟代谢套件使医疗保健提供者能够做出明智的决策并根据患者的个别需求量身定制治疗方案。心臟代谢疾病发生率的不断上升以及对早期检测和个人化护理的重视正在推动这些诊断工具的采用。因此，重症监护诊断市场不断扩大，反映出对先进、精确诊断解决方案的需求。

在测试类型方面，血液学测试部分将在 2024 年至 2032 年期间出现显着增长。在重症监护环境中，及时、准确的血液学结果对于有效的患者管理和治疗决策至关重要。血液疾病的日益普及以及紧急情况和重症监护环境中快速诊断的需求导致了需求的不断增长。因此，血液学检测技术的进步正在推动市场成长并改善患者的治疗结果。

欧洲重症监护诊断市场从 2024 年到 2032 年将呈现适度的复合年增长率。这包括即时监测系统、先进成像和快速诊断分析的整合。推动更好的患者护理，加上监管支援和医疗基础设施投资，推动了该市场的成长。此外，欧洲人口老化和慢性病发病率上升进一步推动了对创新重症监护诊断解决方案的需求不断增长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 老年人口不断增加
      • 慢性病和生活方式相关疾病的盛行率上升
      • 远距医疗服务和远距通讯的采用不断增加
    • 产业陷阱与挑战
      • 分子诊断工具成本高
      • 缺乏熟练的专业人员
  • 成长潜力分析
  • 监管环境
  • 技术景观
    • 核心技术
    • 邻近技术
  • 2023 年定价分析
    • 按地区
    • 按关键人物
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

  • 主要趋势
  • 血糖诊断试剂盒
  • 心臟代谢诊断试剂盒
  • 传染病检测试剂盒
  • 血液学检测试剂盒
  • 凝血诊断试剂盒
  • 癌症标记物检测试剂盒
  • 其他产品

第 6 章：市场估计与预测：按测试类型，2021 - 2032 年

  • 主要趋势
  • 流式细胞仪
  • 血液学检查
  • 微生物学和感染性测试
  • 凝血试验
  • 免疫蛋白
  • 常规和特殊化学
  • 其他测试类型

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 手术室
  • 重症监护室
  • 急诊室
  • 其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 9 章：公司简介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies, Inc.
  • Hologic, Inc.
  • Johnson & Johnson
  • Koninklijke Philips N.V.
  • Medtronic plc
  • Nihon Kohden Corporation
  • Nova Biomedical
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
简介目录
Product Code: 9740

Global Critical Care Diagnostics Market will witness 5.5% CAGR between 2024 and 2032, driven by the rising number of partnerships between leading companies. These collaborations are enhancing the development and distribution of advanced diagnostic technologies crucial for critical care settings. For instance, in June 2024, Radiometer and Etiometry entered into a new commercial partnership aimed at improving clinical decision-making and workflows in hospital environments. Under this collaboration, Etiometry's platform will be integrated with Radiometer's acute care diagnostic solutions, enabling critical care clinicians to access blood gas results, essential clinical data, additional physiological parameters, and AI-driven patient risk analytics all on a single screen.

These tools are essential for the accurate and timely diagnosis of complex conditions in critical care environments. Partnerships also facilitate the sharing of research and development costs, improving efficiency and bringing new products to market faster. As healthcare providers increasingly demand precise and reliable diagnostic solutions to manage critically ill patients, these strategic alliances are pivotal in meeting that need and driving market growth. Consequently, the Critical Care Diagnostics market is expanding rapidly, reflecting the importance of collaborative efforts in advancing healthcare technology.

The overall Critical Care Diagnostics Industry is classified based on the product, test type, end-use, and region.

Based on product, the critical care diagnostics market revenue from the cardiometabolic diagnostic kits segment will register a commendable CAGR from 2024 to 2032. These kits are crucial for assessing and managing conditions such as heart disease, diabetes, and metabolic syndrome, which are prevalent in critical care settings. By providing rapid and accurate diagnostic information, cardiometabolic kits enable healthcare providers to make informed decisions and tailor treatments to individual patient needs. The growing incidence of cardiometabolic disorders and the emphasis on early detection and personalized care are driving the adoption of these diagnostic tools. As a result, the market for critical care diagnostics is expanding, reflecting the need for advanced and precise diagnostic solutions.

In terms of test type, the hematology test segment will register appreciable growth from 2024 to 2032. Hematology tests, including complete blood counts and coagulation profiles, provide essential information on blood disorders, infection, and overall health status. In critical care settings, timely and accurate hematology results are vital for effective patient management and treatment decisions. The growing prevalence of hematological conditions and the need for rapid diagnostics in emergency and intensive care environments contribute to the rising demand. Consequently, advancements in hematology testing technologies are fueling market growth and improving patient outcomes.

Europe critical care diagnostics market will exhibit a modest CAGR from 2024 to 2032. European healthcare systems are increasingly adopting advanced diagnostic technologies to enhance the accuracy and efficiency of critical care management. This includes the integration of real-time monitoring systems, advanced imaging, and rapid diagnostic assays. The push for better patient care, coupled with regulatory support and investment in healthcare infrastructure, drives the growth of this market. Additionally, Europe's aging population and rising incidence of chronic conditions further contribute to the increasing demand for innovative critical care diagnostic solutions.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing geriatric population
      • 3.2.1.2 Rise in the prevalence of chronic diseases and lifestyle-related disorders
      • 3.2.1.3 Rising adoption of telehealth services and remote communications
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of molecular diagnostics tools
      • 3.2.2.2 Lack of skilled professionals
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Pricing analysis, 2023
    • 3.6.1 By region
    • 3.6.2 By key player
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Glucose diagnostic kits
  • 5.3 Cardiometabolic diagnostic kits
  • 5.4 Infectious disease testing kits
  • 5.5 Hematology testing kits
  • 5.6 Coagulation diagnostic kits
  • 5.7 Cancer marker testing kits
  • 5.8 Other products

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Flow cytometry
  • 6.3 Hematology test
  • 6.4 Microbiology and infectious test
  • 6.5 Coagulation test
  • 6.6 Immunoprotein
  • 6.7 Routine and special chemistry
  • 6.8 Other test types

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Operation room
  • 7.3 Intensive care unit
  • 7.4 Emergency rooms
  • 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 South Africa
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 Becton, Dickinson and Company
  • 9.3 Bio-Rad Laboratories, Inc.
  • 9.4 Danaher Corporation
  • 9.5 F. Hoffmann-La Roche Ltd.
  • 9.6 GE HealthCare Technologies, Inc.
  • 9.7 Hologic, Inc.
  • 9.8 Johnson & Johnson
  • 9.9 Koninklijke Philips N.V.
  • 9.10 Medtronic plc
  • 9.11 Nihon Kohden Corporation
  • 9.12 Nova Biomedical
  • 9.13 Siemens Healthineers AG
  • 9.14 Sysmex Corporation
  • 9.15 Thermo Fisher Scientific Inc.